Sigma-Aldrich announced this week that it has signed a definitive agreement to acquire Proligo from specialty chemical giant Degussa, further advancing a wave of consolidation that has been sweeping the RNAi reagent market recently.

According to Sigma-Aldrich, Proligo, which has about 300 employees, racked up sales of $40 million in 2004. Depending on when the acquisition closes, as much as nine months of Proligo’s operating results will be added to Sigma-Aldrich’s top line in 2005, boosting its overall sales growth by 2 percent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

Aug
07
Sponsored by
Qiagen

This webinar will present the results of an evaluation of a web-based variant interpretation software system for clinical next-generation sequencing.